Johnson & Johnson has successfully completed the acquisition of Proteologix, Inc., a biotechnology company specializing in bispecific antibodies for immune-mediated diseases. This strategic acquisition is expected to enhance Johnson & Johnson's capabilities in the development of novel therapies for a range of immune-mediated diseases.